# Elutia Inc.: financial statements, quarterly

ELUT · Nasdaq · CIK 1708527 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elut.md) · [Financials](/companies/elut/financials.md) · [Filings](/companies/elut/filings.md) · [Insiders](/companies/elut/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/elut/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.1](/filings/0001558370-24-015748.md) | [5.9 d](/filings/0001558370-25-002719.md) | [6.7](/filings/0001558370-25-007586.md) | [6.3](/filings/0001558370-25-011590.md) | [3.7](/filings/0001104659-25-110492.md) | [2.8 d](/filings/0001104659-26-027664.md) | [3.0](/filings/0001104659-26-062634.md) | [2.7](/filings/0001104659-26-097292.md) | [3.3](/filings/0001104659-25-110492.md) | [3.3 d](/filings/0001104659-26-027664.md) | [3.1](/filings/0001104659-26-062634.md) | [2.4](/filings/0001104659-26-097292.md) |
| Cost of revenue | $m | [3.3](/filings/0001558370-24-015748.md) | [3.7 d](/filings/0001558370-25-002719.md) | [3.9](/filings/0001558370-25-007586.md) | [3.5](/filings/0001558370-25-011590.md) | [1.9](/filings/0001104659-25-110492.md) | [1.5 d](/filings/0001104659-26-027664.md) | [1.6](/filings/0001104659-26-062634.md) | [1.3](/filings/0001104659-26-097292.md) | [1.5](/filings/0001104659-25-110492.md) | [1.4 d](/filings/0001104659-26-027664.md) | [1.3](/filings/0001104659-26-062634.md) | [1.0](/filings/0001104659-26-097292.md) |
| Gross profit | $m | [2.8](/filings/0001558370-24-015748.md) | [2.1 d](/filings/0001558370-25-002719.md) | [2.8](/filings/0001558370-25-007586.md) | [2.8](/filings/0001558370-25-011590.md) | [1.8](/filings/0001104659-25-110492.md) | [1.3 d](/filings/0001104659-26-027664.md) | [1.4](/filings/0001104659-26-062634.md) | [1.5](/filings/0001104659-26-097292.md) | [1.9](/filings/0001104659-25-110492.md) | [1.9 d](/filings/0001104659-26-027664.md) | [1.8](/filings/0001104659-26-062634.md) | [1.4](/filings/0001104659-26-097292.md) |
| Research and development | $m | [0.6](/filings/0001558370-24-015748.md) | [1.4 d](/filings/0001558370-25-002719.md) | [1.2](/filings/0001558370-25-007586.md) | [1.0](/filings/0001558370-25-011590.md) | [0.7](/filings/0001104659-25-110492.md) | [0.7 d](/filings/0001104659-26-027664.md) | [0.9](/filings/0001104659-26-062634.md) | [1.0](/filings/0001104659-26-097292.md) | [1.1](/filings/0001104659-25-110492.md) | [1.2 d](/filings/0001104659-26-027664.md) | [2.0](/filings/0001104659-26-062634.md) | [2.5](/filings/0001104659-26-097292.md) |
| Operating income | $m | [(7.4)](/filings/0001558370-24-015748.md) | [(8.5) d](/filings/0001558370-25-002719.md) | [(8.5)](/filings/0001558370-25-007586.md) | [(8.5)](/filings/0001558370-25-011590.md) | [(9.2)](/filings/0001104659-25-110492.md) | [(7.5) d](/filings/0001104659-26-027664.md) | [(6.8)](/filings/0001104659-26-062634.md) | [(8.4)](/filings/0001104659-26-097292.md) | [(5.2)](/filings/0001104659-25-110492.md) | [(6.6) d](/filings/0001104659-26-027664.md) | [(6.3)](/filings/0001104659-26-062634.md) | [(8.0)](/filings/0001104659-26-097292.md) |
| Interest expense | $m | [1.4](/filings/0001558370-23-019057.md) | [1.5 d](/filings/0001558370-24-002864.md) | [1.3](/filings/0001558370-24-007987.md) | [1.3](/filings/0001558370-25-011590.md) | [0.1](/filings/0001104659-25-110492.md) | [4.0 d](/filings/0001558370-25-002719.md) | [1.1](/filings/0001558370-25-007586.md) | [0.5](/filings/0001558370-25-011590.md) | [0.3](/filings/0001104659-25-110492.md) | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001558370-24-015748.md) | [(0.0) d](/filings/0001558370-25-002719.md) | [0.0](/filings/0001558370-25-007586.md) | [(0.0)](/filings/0001558370-25-011590.md) | [0.0](/filings/0001104659-25-110492.md) | [0.0 d](/filings/0001104659-26-027664.md) | [0.0](/filings/0001104659-26-062634.md) | [0.0](/filings/0001104659-26-097292.md) | [0.0](/filings/0001104659-25-110492.md) | [(0.0) d](/filings/0001104659-26-027664.md) | [0.1](/filings/0001104659-26-062634.md) | [0.0](/filings/0001104659-26-097292.md) |
| Net income | $m | [(9.7)](/filings/0001558370-24-015748.md) | [(9.3) d](/filings/0001558370-25-002719.md) | [(18.0)](/filings/0001558370-25-007586.md) | [(28.2)](/filings/0001558370-25-011590.md) | [1.3](/filings/0001104659-25-110492.md) | [(9.1) d](/filings/0001104659-26-027664.md) | [(3.9)](/filings/0001104659-26-062634.md) | [(9.6)](/filings/0001104659-26-097292.md) | [(3.9)](/filings/0001104659-25-110492.md) | [70.8 d](/filings/0001104659-26-027664.md) | [(7.5)](/filings/0001104659-26-062634.md) | [(7.6)](/filings/0001104659-26-097292.md) |
| Diluted EPS | $ per share | [(0.57)](/filings/0001558370-24-015748.md) | not reported | [(0.75)](/filings/0001558370-25-007586.md) | [(1.13)](/filings/0001558370-25-011590.md) | [(0.33)](/filings/0001104659-25-110492.md) | not reported | [(0.21)](/filings/0001104659-26-062634.md) | [(0.26)](/filings/0001104659-26-097292.md) | [(0.19)](/filings/0001104659-25-110492.md) | not reported | [(0.17)](/filings/0001104659-26-062634.md) | [(0.17)](/filings/0001104659-26-097292.md) |
| Basic EPS | $ per share | [(0.57)](/filings/0001558370-24-015748.md) | not reported | [(0.75)](/filings/0001558370-25-007586.md) | [(1.13)](/filings/0001558370-25-011590.md) | [0.03](/filings/0001104659-25-110492.md) | not reported | [(0.10)](/filings/0001104659-26-062634.md) | [(0.23)](/filings/0001104659-26-097292.md) | [(0.09)](/filings/0001104659-25-110492.md) | not reported | [(0.17)](/filings/0001104659-26-062634.md) | [(0.17)](/filings/0001104659-26-097292.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [14.5](/filings/0001558370-23-019057.md) | [19.3](/filings/0001558370-25-002719.md) | [12.6](/filings/0001558370-24-007987.md) | [18.2](/filings/0001558370-24-011988.md) | [25.7](/filings/0001558370-24-015748.md) | [13.2](/filings/0001104659-26-027664.md) | [17.4](/filings/0001558370-25-007586.md) | [8.5](/filings/0001558370-25-011590.md) | [4.7](/filings/0001104659-25-110492.md) | [36.4](/filings/0001104659-26-097292.md) | [28.5](/filings/0001104659-26-062634.md) | [19.9](/filings/0001104659-26-097292.md) |
| Current assets | $m | [39.1](/filings/0001558370-23-019057.md) | [31.3](/filings/0001558370-25-002719.md) | [24.0](/filings/0001558370-24-007987.md) | [30.4](/filings/0001558370-24-011988.md) | [37.3](/filings/0001558370-24-015748.md) | [26.2](/filings/0001104659-26-027664.md) | [30.0](/filings/0001558370-25-007586.md) | [22.3](/filings/0001558370-25-011590.md) | [18.4](/filings/0001104659-25-110492.md) | [55.8](/filings/0001104659-26-097292.md) | [48.6](/filings/0001104659-26-062634.md) | [37.2](/filings/0001104659-26-097292.md) |
| Total assets | $m | [54.6](/filings/0001558370-23-019057.md) | [43.4](/filings/0001558370-25-002719.md) | [35.4](/filings/0001558370-24-007987.md) | [41.9](/filings/0001558370-24-011988.md) | [48.4](/filings/0001558370-24-015748.md) | [36.1](/filings/0001104659-26-027664.md) | [39.3](/filings/0001558370-25-007586.md) | [33.8](/filings/0001558370-25-011590.md) | [29.4](/filings/0001104659-25-110492.md) | [62.4](/filings/0001104659-26-097292.md) | [55.2](/filings/0001104659-26-062634.md) | [43.6](/filings/0001104659-26-097292.md) |
| Current liabilities | $m | [44.7](/filings/0001558370-23-019057.md) | [43.0](/filings/0001558370-25-002719.md) | [38.1](/filings/0001558370-24-007987.md) | [39.8](/filings/0001558370-24-011988.md) | [39.7](/filings/0001558370-24-015748.md) | [37.8](/filings/0001104659-26-027664.md) | [36.9](/filings/0001558370-25-007586.md) | [37.9](/filings/0001558370-25-011590.md) | [41.3](/filings/0001104659-25-110492.md) | [25.1](/filings/0001104659-26-097292.md) | [23.7](/filings/0001104659-26-062634.md) | [21.0](/filings/0001104659-26-097292.md) |
| Total liabilities | $m | [84.1](/filings/0001558370-23-019057.md) | [82.0](/filings/0001558370-25-002719.md) | [85.7](/filings/0001558370-24-007987.md) | [106](/filings/0001558370-24-011988.md) | [88.6](/filings/0001558370-24-015748.md) | [82.4](/filings/0001104659-26-027664.md) | [75.8](/filings/0001558370-25-007586.md) | [75.7](/filings/0001558370-25-011590.md) | [73.3](/filings/0001104659-25-110492.md) | [34.7](/filings/0001104659-26-097292.md) | [32.7](/filings/0001104659-26-062634.md) | [27.9](/filings/0001104659-26-097292.md) |
| Long-term debt | $m | [25.3](/filings/0001558370-23-019057.md) | [20.4](/filings/0001558370-25-002719.md) | [19.7](/filings/0001558370-24-007987.md) | [18.9](/filings/0001558370-24-011988.md) | [22.6](/filings/0001558370-24-015748.md) | [22.6](/filings/0001104659-26-027664.md) | [21.8](/filings/0001558370-25-007586.md) | [21.4](/filings/0001558370-25-011590.md) | [21.1](/filings/0001104659-25-110492.md) | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [3.3](/filings/0001558370-24-015748.md) | [2.3](/filings/0001558370-24-007987.md) | [3.4](/filings/0001558370-24-011988.md) | not reported | [1.3](/filings/0001104659-25-110492.md) | [2.5](/filings/0001558370-25-007586.md) | [3.8](/filings/0001558370-25-011590.md) | [5.0](/filings/0001104659-25-110492.md) | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | [3.3](/filings/0001558370-25-002719.md) | [2.3](/filings/0001558370-24-007987.md) | [3.4](/filings/0001558370-24-011988.md) | not reported | [1.3](/filings/0001104659-26-027664.md) | [2.5](/filings/0001558370-25-007586.md) | [3.8](/filings/0001558370-25-011590.md) | [5.0](/filings/0001104659-25-110492.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [(29.5)](/filings/0001558370-24-015748.md) | [(38.6)](/filings/0001104659-26-027664.md) | [(50.3)](/filings/0001558370-25-011590.md) | [(64.3)](/filings/0001104659-25-110492.md) | [(40.2)](/filings/0001104659-25-110492.md) | [(46.3)](/filings/0001104659-26-097292.md) | [(36.5)](/filings/0001104659-26-097292.md) | [(41.8)](/filings/0001104659-26-097292.md) | [(43.9)](/filings/0001104659-25-110492.md) | [27.7](/filings/0001104659-26-097292.md) | [22.5](/filings/0001104659-26-097292.md) | [15.7](/filings/0001104659-26-097292.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.1) d](/filings/0001558370-24-015748.md) | [(9.1) d](/filings/0001558370-25-002719.md) | [(2.6)](/filings/0001558370-25-007586.md) | [(4.3) d](/filings/0001558370-25-011590.md) | [(3.4) d](/filings/0001104659-25-110492.md) | [(12.3) d](/filings/0001104659-26-027664.md) | [(8.9)](/filings/0001104659-26-062634.md) | [(8.2) d](/filings/0001104659-26-097292.md) | [(2.9) d](/filings/0001104659-25-110492.md) | [(24.8) d](/filings/0001104659-26-027664.md) | [(7.8)](/filings/0001104659-26-062634.md) | [(8.5) d](/filings/0001104659-26-097292.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001558370-24-015748.md) | [0.0 d](/filings/0001558370-25-002719.md) | [0.0](/filings/0001558370-25-007586.md) | [(0.0) d](/filings/0001558370-25-011590.md) | [0.5 d](/filings/0001104659-25-110492.md) | [0.1 d](/filings/0001104659-26-027664.md) | [0.3](/filings/0001104659-26-062634.md) | [0.1 d](/filings/0001104659-26-097292.md) | [0.6 d](/filings/0001104659-25-110492.md) | [0.9 d](/filings/0001104659-26-027664.md) | [0.5](/filings/0001104659-26-062634.md) | [0.1 d](/filings/0001104659-26-097292.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q3 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.7](/filings/0001558370-23-019057.md) | [16.1](/filings/0001558370-24-007987.md) | [16.2](/filings/0001558370-24-011988.md) | [17.0](/filings/0001558370-24-015748.md) | [23.9](/filings/0001558370-25-007586.md) | [24.9](/filings/0001558370-25-011590.md) | [35.5](/filings/0001104659-25-110492.md) | [42.9](/filings/0001104659-26-062634.md) | [46.3](/filings/0001104659-26-097292.md) | [47.0](/filings/0001104659-25-110492.md) | [43.0](/filings/0001104659-26-062634.md) | [44.2](/filings/0001104659-26-097292.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.